Jula Inrig Travere Therapeutics, Inc. (TVTX) insider trading activity

Jula Inrig is CHIEF MEDICAL OFFICER of Travere Therapeutics, Inc.. Currently has a direct ownership of 86,311 shares of TVTX, which is worth approximately $2.98 Million. The most recent transaction as insider was on Jan 06, 2026, when has been sold 445 shares (Common Stock) at a price of $37.75 per share, resulting in proceeds of $16,798. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 86.3K

2.79% 3M change

45.2% 12M change

Total Value Held $2.98 Million

Jula Inrig Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 06 2026	SELL Open market or private sale	$16,798 $37.75 p/Share	445 Reduced 0.51%	86,311 Common Stock
Jan 05 2026	SELL Open market or private sale	$81,605 $40.18 p/Share	2,031 Reduced 2.29%	86,756 Common Stock
Dec 24 2025	SELL Open market or private sale	$630,000 $42.0 p/Share	15,000 Reduced 14.45%	88,787 Common Stock
Dec 24 2025	BUY Exercise of conversion of derivative security	$133,950 $8.93 p/Share	15,000 Added 12.63%	103,787 Common Stock
Jul 01 2025	SELL Open market or private sale	$11,939 $14.65 p/Share	815 Reduced 0.91%	88,787 Common Stock
Feb 12 2025	SELL Open market or private sale	$60,425 $23.53 p/Share	2,568 Reduced 2.79%	89,602 Common Stock
Feb 10 2025	BUY Exercise of conversion of derivative security	-	8,000 Added 7.99%	92,170 Common Stock

Feb 04 2025	SELL Open market or private sale	$21,437 $20.11 p/Share	1,066 Reduced 1.25%	84,170 Common Stock
Feb 03 2025	SELL Open market or private sale	$84,644 $20.12 p/Share	4,207 Reduced 4.7%	85,236 Common Stock
Jan 31 2025	BUY Grant, award, or other acquisition	-	30,000 Added 25.12%	89,443 Common Stock
Jan 06 2025	SELL Open market or private sale	$8,254 $18.76 p/Share	440 Reduced 0.73%	59,443 Common Stock
Jan 03 2025	SELL Open market or private sale	$39,460 $19.1 p/Share	2,066 Reduced 3.34%	59,883 Common Stock
Sep 10 2024	SELL Open market or private sale	$8,878 $12.98 p/Share	684 Reduced 1.09%	61,949 Common Stock
Sep 09 2024	SELL Open market or private sale	$25,240 $11.52 p/Share	2,191 Reduced 3.38%	62,633 Common Stock
Sep 05 2024	BUY Grant, award, or other acquisition	-	6,750 Added 9.43%	64,824 Common Stock
Feb 01 2024	SELL Open market or private sale	$18,544 $8.53 p/Share	2,174 Reduced 3.61%	58,074 Common Stock
Jan 31 2024	BUY Grant, award, or other acquisition	-	25,000 Added 29.33%	60,248 Common Stock
Jan 04 2024	SELL Open market or private sale	$4,034 $9.17 p/Share	440 Reduced 1.23%	35,248 Common Stock
Jan 03 2024	SELL Open market or private sale	$19,614 $9.48 p/Share	2,069 Reduced 5.48%	35,688 Common Stock
Jan 31 2023	BUY Grant, award, or other acquisition	-	20,250 Added 34.91%	37,757 Common Stock
Jan 05 2023	SELL Open market or private sale	$9,171 $20.75 p/Share	442 Reduced 2.46%	17,507 Common Stock
Jan 04 2023	SELL Open market or private sale	$42,558 $20.75 p/Share	2,051 Reduced 10.26%	17,949 Common Stock
Jan 01 2022	BUY Grant, award, or other acquisition	-	20,000 Added 50.0%	20,000 Common Stock

Jula Inrig

CHIEF MEDICAL OFFICER

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TVTX shares.

Notify only if

Value

Insider Trading

Get notified when an Travere Therapeutics, Inc. insider buys or sells TVTX shares.

Notify only if

Operation

Value

Type

News

Receive news related to Travere Therapeutics, Inc.

Track Activities on TVTX

Account